Future of IIM TreatmentPreview
Open in TheBrain

IVIg

The role of IVIg has strengthened materially in the last several years because it now has high-quality randomized evidence showing clinically meaningful benefit across multiple dermatomyositis domains (muscle, skin, and several “systemic” features), with a safety profile that is generally manageable when thromboembolic risk is explicitly mitigated. In the phase 3, randomized, double-blind, placebo-controlled ProDERM trial, *95 adults *with active dermatomyositis were randomized to IVIg 2.0 g/kg (Octagam 10%) or placebo every 4 weeks for 16 weeks, with an open-label extension through week 40 in which all participants received IVIg.

The primary endpoint was a composite clinical response defined by ACR/EULAR Total Improvement Score (TIS) ≥20 at week 16 with no confirmed deterioration. At week 16, 79% (37/47) of the IVIg group achieved response versus 44% (21/48) with placebo (absolute difference 35 percentage points; 95% CI 17–53; P<0.001), establishing IVIg as an efficacy-proven disease-modifying option rather than a purely “rescue” therapy.

Mean TIS separation was also substantial: at week 16, mean TIS was 48.4±24.4 with IVIg versus 21.6±20.2 with placebo, and the treatment effect emerged early (mean TIS 24.4 vs 10.7 by week 4). Time-to-response analyses further reinforce the clinical feel of IVIg as a relatively rapid steroid-sparing tool: the median time to minimal improvement was 35 days with IVIg versus 115 days with placebo, and time to moderate improvement was 85 vs 197 days.

Confirmed deterioration during the placebo-controlled phase was uncommon but occurred only in the placebo arm (0% IVIg vs 6% placebo), consistent with real-world impressions that IVIg can stabilize active disease while other agents are being optimized. Because week 16–40 outcomes were obtained during open-label exposure, they are descriptive rather than inferential, but they show that participants initially assigned to placebo “catch up” after switching to IVIg, supporting a consistent biologic effect rather than regression to the mean. [1]

Cutaneous outcomes have become a major driver of IVIg adoption, and ProDERM’s dermatology-focused post-hoc analyses provide granular data. Using the CDASI activity score (CDASI-A), IVIg produced a markedly larger mean improvement by week 16: −9.36 (95% CI −12.52 to −6.19) vs −1.16 (95% CI −3.32 to 0.99) with placebo (P<0.0001); least-squares mean changes were −10.3 vs −2.3, with an LS mean difference of −8.0 (95% CI −11.5 to −4.6; P<0.0001).

Importantly, these improvements were not confined to mild skin disease: when stratified by baseline CDASI-A severity (mild, moderate, severe), IVIg consistently improved CDASI-A, and placebo patients who crossed over to IVIg achieved similar skin control by week 40. A patient-centered framing is also available: a >35% reduction in CDASI-A (a threshold linked to meaningful quality-of-life improvement in Skindex-29 subscales) occurred in 65.9% (29/44) on IVIg versus 25.6% (11/43) on placebo at week 16, a difference that matches bedside experience that IVIg can meaningfully “move the needle” on refractory rash. [2]

Beyond muscle and skin, ProDERM sub-analyses support IVIg’s role in several extramuscular manifestations that often determine hospitalization risk and overall disease burden.

Using the Myositis Disease Activity Assessment Tool (MDAAT) VAS domains, IVIg was associated (baseline→week 16) with mean reductions in pulmonary (−37.7%; P=0.001), skeletal (−52.6%; P<0.001), constitutional (−44.4%; P<0.001), and gastrointestinal activity (−49.2%; P=0.005), whereas placebo showed no corresponding improvement except constitutional VAS.

Clinically legible categorical shifts were also reported: proportions with arthritis fell from 36.2% to 17.8% (P=0.01), arthralgia from 68.1% to 0.0% (P<0.001), and fatigue from 68.1% to 3.3% (P=0.008) by week 16 in the IVIg group. Over the full 40 weeks (descriptive, pooled exposure), features that often prompt escalation—dysphagia (40.0%→18.4%; P<0.001) and dysphonia (20.0%→8.1%; P=0.04)—also decreased, supporting the common practice of favoring IVIg when bulbar symptoms are prominent or when infection risk makes deeper immunosuppression undesirable. [4]

Safety is the necessary counterweight, and ProDERM’s detailed safety analysis clarifies where vigilance matters most. Across 664 IVIg infusion cycles, treatment-related TEAEs were more frequent with IVIg than placebo during the blinded phase (57.7% vs 22.9%), and 8 patients discontinued due to IVIg-related adverse events.

The pivotal risk signal is thromboembolism: 8 thromboembolic events occurred in 6 IVIg-exposed patients, with 6 events in 5 patients considered possibly/probably IVIg-related. Patients who developed thromboembolic events had a higher burden of baseline risk factors than those who did not, and a practical mitigation emerged: lowering infusion rate reduced thromboembolic event rates, and no thromboembolic events occurred at the lower IVIg dose in the extension where dose reduction (1 g/kg) was permitted for stable patients.

No hemolytic transfusion reactions or deaths were observed. Translating this to bedside practice strengthens your concluding sentence: IVIg is most attractive when rapid steroid-sparing is needed (including dysphagia), but it should be paired with an explicit thromboembolic risk assessment and conservative infusion strategy—especially in patients with baseline risk factors—because that is where preventable harm concentrates. [3]

References (AMA)

  1. Aggarwal R, Charles-Schoeman C, Schessl J, et al; ProDERM Study Group. Trial of Intravenous Immune Globulin in Dermatomyositis. N Engl J Med. 2022;387(14):1264-1278. doi:10.1056/NEJMoa2117912
  2. Werth VP, Aggarwal R, Charles-Schoeman C, et al. Efficacy of intravenous immunoglobulins (IVIg) in improving skin symptoms in patients with dermatomyositis: a post-hoc analysis of the ProDERM study. EClinicalMedicine.2023;64:102234. doi:10.1016/j.eclinm.2023.102234
  3. Aggarwal R, Schessl J, Bata-Csörgő Z, et al; ProDERM Investigators. Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study. Arthritis Res Ther. 2024;26:27. doi:10.1186/s13075-023-03232-2
  4. Aggarwal R, Schessl J, Bata-Csörgő Z, et al; ProDERM investigators. Efficacy of Intravenous Immunoglobulin for Systemic Manifestations of Dermatomyositis Beyond Muscular and Cutaneous: Sub-analysis of the ProDERM Study. Rheumatol Ther. 2025;12(5):855-871. doi:10.1007/s40744-025-00775-5